This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Arestin - Use in Subjects With Peri-Implantitis

This study has been completed.
Information provided by (Responsible Party):
OraPharma Identifier:
First received: February 21, 2012
Last updated: June 25, 2014
Last verified: June 2014

The objective of the study is to evaluate the safety and effectiveness of Arestin (minocycline HCl) 1 mg Microspheres in the treatment of subjects with peri-implantitis, when used in combination with mechanical debridement.

The hypothesis of the study is that Arestin in combination with mechanical debridement is more effective in the treatment of peri-implantitis when compared to mechanical debridement alone. The primary efficacy measure will be the reduction of probing depth at Day 180 as measured at qualifying implant sites.

Condition Intervention Phase
Peri-Implantitis Drug: Minocycline HCl Microspheres Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multi-Center Phase 3 Trial of Minocycline HCl 1mg Microspheres for the Use in Subjects With Peri-Implantitis

Resource links provided by NLM:

Further study details as provided by OraPharma:

Primary Outcome Measures:
  • Change in mean Probing Depth of qualifying implant sites [ Time Frame: Baseline to Day 180 ]

Secondary Outcome Measures:
  • Change in percentage of qualifying implants with Bleeding on Probing [ Time Frame: Baseline to Day 180 ]
  • Change in mean Probing Depth of qualifying implant sites [ Time Frame: Baseline to Day 90 ]
  • Change in percentage of qualifying implants with Bleeding on Probing [ Time Frame: Baseline to Day 90 ]

Enrollment: 215
Study Start Date: April 2012
Study Completion Date: June 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment
Treatment (minocycline HCl microspheres, 1mg) administered at Baseline (following randomization) and Day 90 to qualifying implant sites, plus full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180.
Drug: Minocycline HCl Microspheres
Other Name: Arestin (brand name)
No Intervention: Control
Full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180; no treatment


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A minimum of one osseointegrated implant with a diagnosis of peri-implantitis
  • Absence of any significant oral soft tissue pathology
  • At least one peri-implant site with an average of 2 probing depth readings between 5mm and 7mm (inclusive) when using a light force and with bleeding on probing within 30 seconds of the probing
  • Confirmed evidence of pathologic bone loss
  • At least 1mm of keratinized gingiva present around the implant

Exclusion Criteria:

  • Pregnancy
  • Allergy to tetracycline-class drug(s)
  • Systemic medical condition(s) requiring antibiotic prophylaxis prior to invasive dental procedures
  • Presence of active systemic infectious disease such as hepatitis, HIV, history of tuberculosis
  • Diagnosis of clinically significant or unstable organic disease, or compromised healing potential
  • Signs of untreated advanced periodontal disease and/or poor oral hygiene
  • Subjects having a probing depth greater than 8mm at time of enrollment
  • Subjects presenting with mobility of any dental implant
  • Subjects having a qualifying implant under occlusal trauma or overloaded (as determined by the investigator)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01539564

United States, California
UCLA School of Dentistry - Oral and Maxillofacial Surgery
Los Angeles, California, United States, 90095
United States, Florida
University of Florida College of Dentistry
Gainsville, Florida, United States, 32610
United States, Georgia
Georgia Regents University
Augusta, Georgia, United States, 30912
United States, Maryland
University of Maryland, School of Dentistry
Baltimore, Maryland, United States, 21201
United States, Minnesota
University of Minnesota - School of Dentistry
Minneapolis, Minnesota, United States, 55355
United States, North Carolina
University of North Carolina, General Oral Health Center
Chapel Hill, North Carolina, United States, 27599
United States, Ohio
Ohio State University College of Dentistry
Columbus, Ohio, United States, 43210
United States, Virginia
The Periodontal-Implant Institute
McLean, Virginia, United States, 22101
United States, Washington
University of Washington, School of Dentistry
Seattle, Washington, United States, 98195-7444
University of Dusseldorf, Poliklinik fur Zahnerhaltung, Parodontologie und Endodontologie
Dusseldorf, Germany, 40225
Kristianstad University, Department of Periodontology
Kristianstad, Sweden, SE-291 88
United Kingdom
Eastman Dental Institute, University College of London
London, United Kingdom, WC1X 8LD
Sponsors and Collaborators
Principal Investigator: Thomas Flemmig, DMD, MBA University of Washington, School of Dentistry
  More Information

Responsible Party: OraPharma Identifier: NCT01539564     History of Changes
Other Study ID Numbers: OP-P-5267
Study First Received: February 21, 2012
Last Updated: June 25, 2014

Additional relevant MeSH terms:
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases
Anti-Bacterial Agents
Anti-Infective Agents processed this record on September 21, 2017